全文获取类型
收费全文 | 213篇 |
免费 | 15篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 6篇 |
基础医学 | 24篇 |
口腔科学 | 2篇 |
临床医学 | 17篇 |
内科学 | 49篇 |
皮肤病学 | 4篇 |
神经病学 | 9篇 |
特种医学 | 12篇 |
外科学 | 57篇 |
综合类 | 11篇 |
预防医学 | 17篇 |
药学 | 9篇 |
中国医学 | 2篇 |
肿瘤学 | 8篇 |
出版年
2024年 | 1篇 |
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 10篇 |
2017年 | 8篇 |
2016年 | 7篇 |
2015年 | 8篇 |
2014年 | 10篇 |
2013年 | 16篇 |
2012年 | 6篇 |
2011年 | 6篇 |
2010年 | 12篇 |
2009年 | 9篇 |
2008年 | 7篇 |
2007年 | 5篇 |
2006年 | 9篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有232条查询结果,搜索用时 15 毫秒
91.
92.
《Diagnostic Histopathology》2016,22(10):378-383
Patients with metabolic bone disease are usually cared for by endocrinologists. Pathologists may examine specimens if fragility fractures occur or if a bone biopsy is required. Some metabolic bone diseases have distinctive histologic features such as tunneling resorption in hyperparathyroidism, wide osteoid seams in osteomalacia, and bone marrow edema in transient osteoporosis. The histologic changes must always be correlated with clinical and radiographic features. 相似文献
93.
Aluminum accumulation in individuals with normal renal function 总被引:1,自引:0,他引:1
S M Ott 《American journal of kidney diseases》1985,6(5):297-301
In individuals with normal renal function, oral aluminum may be absorbed, but the kidneys are able to excrete the load, and significant pathology is not seen. If aluminum is given parenterally, however, it can accumulate in tissues and lead to osteomalacia or aplastic bone lesions. Low calcitriol and PTH levels are often seen, and may contribute to the bone disease. These findings in individuals with normal renal function add to the growing body of evidence that aluminum is toxic to bone. 相似文献
94.
Alendronate improves vitamin d-resistant osteopenia triggered by gastrectomy in patients with gastric cancer followed long term 总被引:1,自引:0,他引:1
Yutaka?Suzuki Yoshio?Ishibashi Nobuo?Omura Naruo?Kawasaki Hideyuki?Kashiwagi Katsuhiko?Yanaga Masahiro?Abo Mitsuyoshi?UrashimaEmail author 《Journal of gastrointestinal surgery》2005,9(7):955-960
Gastrectomy/gastric bypass has been used for patients with gastric cancer, and its application is now expanding to treating
patients with morbid obesity, the prevalence of which is increasing worldwide. It is well known that gastrectomy leads to
osteopenia, but the underlying pathophysiology and optimum treatments for this disorder have not been delineated. We followed
13 patients who showed progressive osteopenia (bone mineral density T-score <-2.4 SD) after gastrectomy/gastric bypass due
to gastric cancer and who were resistant to long-term treatment (mean, 6 years) of active vitamin D3 and prospectively studied
the effects of alendronate, a bisphosphonate, on osteopenia-related parameters for 2 years. Oral administration of alendronate
in addition to vitamin D3 led to remarkable improvement within 2 years, not only in clinical symptoms, such as radial bone
fractures and lumbar pain, but also in parameters for osteopenia, including decreased bone mineral density of the lumbar spine
(P < 0.01), decreased concentrations of calcium (P < 0.05), increased urine levels of deoxypyridinoline (P < 0.01), increased serum levels of bone-specific alkaline phosphatase (P < 0.01), increased serum levels of osteocalcin (P < 0.01), and increased serum levels of intact parathyroid hormone (P < 0.05), although body weight did not alter. These results suggest that bisphosphonate may improve osteopenia after gastrectomy/gastric
bypass. 相似文献
95.
髌骨软化症中西医治疗进展 总被引:1,自引:0,他引:1
髌骨软化症是一种髌骨软骨退行性病变,西医治疗早中期主要提倡保守治疗,包括关节腔内注射玻璃酸钠、口服硫酸氨基葡萄糖、非甾体类抗炎药等;晚期建议手术治疗,均有一定效果及毒副作用.中医认为本病多因伤后气血不足,瘀血阻滞风寒湿邪侵袭,或因年老体弱,肝肾亏虚,气血亏虚,卫外不固,不能濡润关节,风寒湿邪乘虚而入而发病,治疗主要有中药内服、外敷、熏洗、针灸、推拿等法,急则治其标,缓则治其本,因人制宜,标本兼顾.中西医结合治疗可取长补短. 相似文献
96.
目的 数值研究实体肿瘤内外三维微血管网及间质内的血液动力学。方法 数值生成实体肿瘤内外三维微血管网,根据Poiseuille定律和Darcy定律分别计算微血管内压强及肿瘤组织间质压、组织液流速。结果 肿瘤外部微血管内压强迅速降低,肿瘤内部微血管压强变化很小,可视为常数;肿瘤组织间质压呈现‘内高且平,外低且陡’的分布,组织液流速与之相反。结论 本模型得到了较为有效的肿瘤内外三维血管网结构;血液动力学计算结果与生理实际基本吻合,为研究肿瘤内药物输运提供了可信的模型及方法。 相似文献
97.
98.
O. Emodi A. Rachmiel D. Tiosano R.M. Nagler 《International journal of oral and maxillofacial surgery》2018,47(10):1295-1298
Tumour-induced osteomalacia (TIO) is a rare paraneoplastic form of renal phosphate wasting that results in severe hypophosphatemia, defective vitamin D metabolism, and osteomalacia. In the case reported here, maxillary TIO was not diagnosed for 6 years, although initial complaints were reported when the patient was 12 years old. Meanwhile she suffered from profound growth limitation, pain, weakness, and spontaneous multiple bone fractures, culminating in complete loss of ambulatory ability and severe limitation in daily activities. At age 18 years, she finally received an accurate diagnosis and definitive treatment was administered. She underwent a partial maxillectomy with complete removal of the tumour, resulting in a full cure. Shortly afterwards the patient regained the ability to walk, no longer needing the wheelchair to which she had been confined. This definitive diagnosis was based on three modalities: (1) fibroblast growth factor 23 analysis (high levels of the secreted hormone were found on the left side of the maxilla in the facial vein and pterygoid plexus, pinpointing the tumour location), (2) octreotide scan, and (3) 68Ga-DOTA-NOC-PET/CT. TIO removal via partial maxillectomy led to a complete reversal of this patient’s health condition, restoring her ability to walk and function. The importance of prompt employment of these diagnostic modalities and the high level of clinical suspicion required in such cases are clear. 相似文献
99.
Edward M. Brown 《Biochemical pharmacology》2010,80(3):297-619
Calcimimetics, which activate the extracellular calcium (Cao2+)-sensing receptor in the parathyroid and other tissues participating in Cao2+ homeostasis, were the first described allosteric activators of a G-protein-coupled receptor. Cinacalcet, the only calcimimetic currently approved for human use, is used clinically for treating secondary hyperparathyroidism (e.g., overactivity of parathyroid glands) in patients being dialyzed for chronic kidney disease. By sensitizing the parathyroids to Cao2+, cinacalcet lowers the circulating parathyroid hormone (PTH) level. It also reduces serum calcium and phosphate, changes increasing the percentage of patients achieving the guidelines recommended by the National Kidney Foundation (NKF) for these minerals. Studies are underway addressing whether better adherence to these guidelines in patients receiving cinacalcet reduces cardiovascular disease and related mortality, which are both common is the dialysis population. The second approved use of cinacalcet is for treating hypercalcemia in patients with inoperable parathyroid carcinoma. In this setting, it provides the first medical therapy chronically lowering serum calcium concentration in this condition, albeit not to normal in most patients. Its effect on the long-term prognosis of these patients, if any, is presently unclear. “Off-label” administration of cinacalcet [i.e., not yet approved by the US Food and Drug Administration (FDA)] effectively lowers serum calcium and/or PTH in various other forms of hyperparathyroidism and increases serum phosphate in renal phosphate-wasting syndromes by reducing PTH-induced phosphaturia. In the future, the drug could conceivably be utilized to modulate the activity of the CaSR in other tissues (i.e., kidney, colon) in therapeutically desirable ways. 相似文献
100.